Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia in Children: Remission Induction With All-transretinoic Acid (ATRA) and Arsenic Trioxide (As2O3). Consolidation With Daunorubicin(DNR)+Ara-c or DNR Alone.
Some studies suggest patients with high-risk disease should be treated with intensified
doses of anthracycline, or intermediate/ high-dose Ara-C or As2O3 as an early consolidation,
so as to decrease the risk of relapse.However, a higher cumulative dose of anthracycline may
lead to cardiac toxicity, especially for children. In addition, containing Ara-C will led to
more therapy-related toxicity. The benefit to add Ara-C to the schedules is questionable and
remains a matter of investigation in children.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the impact of the addition of Ara-C to DNR courses of consolidation for patients on the disease-free survival
Xiaofan Zhu, MD
Department of Pediatrics, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
China: Ministry of Health